The CSV file with the chemogenomic set can be downloaded from here.
Compound name
Protein family
Target name
Affinity Biochemical (nM)
Affinity On-target Cellular (nM)
Chemogenomic Set
Recommended Concentration
More
SGC-CDKL5/GSK3-1N
Protein Kinase
GSK3A
IC50 > 10000
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002313a
SMILES
Cn1cc(NC(=O)c2cc(F)cc(F)c2)c(C(=O)NC2CCNCC2)n1
InChIKey
ODZBDODDFLVDQZ-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Negative control for SGC-CDKL5_GSK3
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Compound image 
SGC-CDKL5/GSK3-1N
Protein Kinase
GSK3B
IC50 > 10000
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002313a
SMILES
Cn1cc(NC(=O)c2cc(F)cc(F)c2)c(C(=O)NC2CCNCC2)n1
InChIKey
ODZBDODDFLVDQZ-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Negative control for SGC-CDKL5_GSK3
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Compound image 
SGC-CDKL5_GSK3
Protein Kinase
CDKL5
IC50 0 6.5
IC50 0 3.5
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002314a
SMILES
O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1
InChIKey
NIHAFOURWLZLFN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
EIEE2, CFAP247
Mode of action
inhibitor
Negative control
SGC-CDKL5/GSK3-1N
Affinity biochemical assay type
KinaseSeeker homogenous competition binding assay (Luceome Biotechnologies)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
DiscoverX (scanMAX)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM
Selectivity Source Knowledge
Compound image 
SGC-CDKL5_GSK3
Protein Kinase
GSK3A
IC50 0 4
IC50 0 10
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002314a
SMILES
O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1
InChIKey
NIHAFOURWLZLFN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
inhibitor
Negative control
SGC-CDKL5/GSK3-1N
Affinity biochemical assay type
Enzymatic radiometric assays (Eurofins)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
DiscoverX (scanMAX)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM
Selectivity Source Knowledge
Compound image 
SGC-CDKL5_GSK3
Protein Kinase
GSK3B
IC50 0 9
IC50 0 35
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002314a
SMILES
O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1
InChIKey
NIHAFOURWLZLFN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
inhibitor
Negative control
SGC-CDKL5/GSK3-1N
Affinity biochemical assay type
Enzymatic radiometric assays (Eurofins)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
DiscoverX (scanMAX)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM
Selectivity Source Knowledge
Compound image 
SGC-GSK3-1
Protein Kinase
GSK3A
IC50 0 1
IC50 0 4.6
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002315a
SMILES
O=C(NCC1CCOCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F
InChIKey
OCQCKUTZHBQNEI-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
inhibitor
Negative control
SGC-CDKL5/GSK3-1N
Affinity biochemical assay type
Enzymatic radiometric assays (Eurofins)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
DiscoverX (scanMAX)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 1 µM, closest targets as % of control: GSK3A (0%), GSK3B (0.2%), DYRK1A (0.4%), ICK(5.7%), DYRK2 (8.3%), DYRK1B (10%), MAPK8 (16%), CDK4 (20%), RPS6KA4 (29%), CLK1 (30%), CDKL5 (30%), CDK7 (31%), MAPK10 (31%), CLK4 (32%), CLK2 (34%), CDKL2 (77%), CDKL1(93%), CDKL3(100%); In-vitro potency of closest targets (enzymatic radiometric assays, Eurofins): IC50(DYRK1A) = 170 nM, IC50(ICK) = 520 nM, IC50(DYRK2) = 800 nM, IC50(DYRK1B) = 47 nM, IC50(MAPK8) >10000 nM, IC50(CDK4) = 3800 nM, IC50(RPS6KA4) >10000 nM, IC50(CLK1) = 620 nM, IC50(CDKL5) = 840 nM, IC50(CDK7) >10000 nM, IC50(MAPK10) = 2900 nM, IC50(CLK4) = 760 nM, IC50(CLK2) = 800 nM; In-cellular potency (NanoBRET assay, HEK293T cells): IC50(DYRK1B) = 2400 nM, IC50(CDKL5) = 1400 nM
Selectivity Source Knowledge
Compound image 
SGC-GSK3-1
Protein Kinase
GSK3B
IC50 0 2
IC50 0 12
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002315a
SMILES
O=C(NCC1CCOCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F
InChIKey
OCQCKUTZHBQNEI-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
inhibitor
Negative control
SGC-CDKL5/GSK3-1N
Affinity biochemical assay type
Enzymatic radiometric assays (Eurofins)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET assay (HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
DiscoverX (scanMAX)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 1 µM, closest targets as % of control: GSK3A (0%), GSK3B (0.2%), DYRK1A (0.4%), ICK(5.7%), DYRK2 (8.3%), DYRK1B (10%), MAPK8 (16%), CDK4 (20%), RPS6KA4 (29%), CLK1 (30%), CDKL5 (30%), CDK7 (31%), MAPK10 (31%), CLK4 (32%), CLK2 (34%), CDKL2 (77%), CDKL1(93%), CDKL3(100%); In-vitro potency of closest targets (enzymatic radiometric assays, Eurofins): IC50(DYRK1A) = 170 nM, IC50(ICK) = 520 nM, IC50(DYRK2) = 800 nM, IC50(DYRK1B) = 47 nM, IC50(MAPK8) >10000 nM, IC50(CDK4) = 3800 nM, IC50(RPS6KA4) >10000 nM, IC50(CLK1) = 620 nM, IC50(CDKL5) = 840 nM, IC50(CDK7) >10000 nM, IC50(MAPK10) = 2900 nM, IC50(CLK4) = 760 nM, IC50(CLK2) = 800 nM; In-cellular potency (NanoBRET assay, HEK293T cells): IC50(DYRK1B) = 2400 nM, IC50(CDKL5) = 1400 nM
Selectivity Source Knowledge
Compound image 
Takinib
Protein Kinase
MAP3K7
IC50 = 5.46
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002327a
SMILES
CCCn1c(NC(=O)c2cccc(C(N)=O)c2)nc2ccccc21
InChIKey
UOZVVPXKJGOFIG-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
MEKK7
Mode of action
Inhibitor
Affinity biochemical assay type
Radiometric assay (Activity of purified TAK1-TAB1 protein using 5 µM ATP)
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (MRC Dundee)
Selectivity platform number of targets
140
Selectivity remarks
Screened at 10 µM, closest targets as % on control: MAP3K7 (2%), CLK2 (4%), IRAK1 (4%), IRAK4 (7%), GCK (9%), MINK1 (9%), CSNK1G2 (13%), full screening data available as supporting information; In-vitro potency (enzymatic assay, MRC Dundee): IC50(MAP3K7) = 9.5 nM, IC50(IRAK4) = 120 nM, IC50(IRAK1) = 390 nM, IC50(GCK) = 430 nM, IC50(CLK2) = 430 nM, IC50(MINK1) = 1900 nM, https://pubmed.ncbi.nlm.nih.gov/28820959/; Kinase proteome profiling in RA-FLS cells, against 45 kinases, closest targets as % of activity: LCK (42.6%), full screening data available as supporting info, https://pubmed.ncbi.nlm.nih.gov/31847895/;
Selectivity Source Knowledge
Compound image 
TP-060
Transferase
UGCG
IC50 = 31
EC50 = 7.6
Other targets set
1 µM
Compound EUbOPEN ID
EUB0002336a
SMILES
CC(C)(O)c1ccc(N2Cc3c(ccnc3-c3ccc(F)cc3OCC(F)(F)F)C2=O)cc1
InChIKey
OAZAPIKYVGRNCO-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
GCS, GLCT1
Mode of action
Allosteric inhibitor
Negative control
TP-060n
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Glucosylceramide lowering assay (using GBA mutant human fibroblast cells)
Affinity on-target cellular source knowledge
Selectivity platform
SAFETYscan (DiscoverX)
Selectivity platform number of targets
47
Selectivity remarks
Screened against a panel of receptors, ion channels, and other enzymes (enzymatic assays), in-vitro potency of closest target: IC50(SLC6A4) = 0.31 µM, IC50(HTR1B) = 2.8 µM, IC50(CHRNA4) = 6.5 µM, other targets IC50 >10 µM, full screening data available as supplement information;
Selectivity Source Knowledge
Compound image 
TP-060n
Transferase
UGCG
IC50 > 100000
EC50 > 10000
Other targets set
1 µM
Compound EUbOPEN ID
EUB0002337a
SMILES
COc1cccc(-c2nccc3c2CN(c2ccccc2)C3=O)c1
InChIKey
CECLXQDMAJQBCR-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
GCS, GLCT1
Mode of action
Negative control for TP-060
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Glucosylceramide lowering assay (using GBA mutant human fibroblast cells)
Affinity on-target cellular source knowledge
Compound image 
Ulixertinib
Protein Kinase
MAPK1
IC50 < 0.3
IC50 = 4100
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002341a
SMILES
CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1
InChIKey
KSERXGMCDHOLSS-LJQANCHMSA-N
NCBI gene ID
UniProt ID
Synonyms
ERK, ERK2, p41mapk, MAPK2
Mode of action
Reversible covalent inhibitor
Affinity biochemical assay type
Rapidfire Mass Spectrometry Inhibition of Catalysis Assay (Km ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Immunoblot assay (phosphorylation of ERK using A375 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Proteomics (Kinobeads assay using lysate from K-562, COLO 205, SK-N-BE(2), and MV-4-11 cells)
Selectivity platform number of targets
300
Selectivity remarks
In-vitro potency (competition binding assay) of closest targets in the screen: Kd(MAPK3) = 160 nM, Kd(MAPK1) = 183 nM, Kd(TAO1) = 388 nM, Kd(PRKD2) = 6336 nM, full screening data available in paper https://www.science.org/doi/10.1126/science.aan4368, and Chembl;
Selectivity Source Knowledge
Compound image 
BAY-7081
Hydrolase
PDE9A
IC50 0 15
EC50 0 995
Other targets set
1 µM
Compound EUbOPEN ID
EUB0002354aCl
SMILES
CCC[C@H]1CNCC2=C1NC(C(C#N)=C2N3CCC4(CC4)CC3)=O.Cl
InChIKey
NPPMVTBTTJNVKP-ZDUSSCGKSA-N
NCBI gene ID
UniProt ID
Synonyms
HSPDE9A2
Mode of action
inhibitor
Negative control
BAY-7081
Affinity biochemical assay type
Scintillation Proximity Assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Cellular PDE9A assay (using recombinant CHO cell line stably expressing murine PDE9A)
Affinity on-target cellular source knowledge
Selectivity platform
Eurofins Panlabs screen
Selectivity platform number of targets
75
Selectivity remarks
Screened at 10 µM (panel of GPCRs, ion channels, transporters), closest targets as % of inhibition: PDE1A (7.7%), PDE2A (3.5%), PDE3A (-1.3%), PDE3B (0.8%), PDE4A (6.8%), PDE4B (10.6%), PDE4C (28.6%), PDE4D (19.1%), PDE5A (12.2%), PDE6 (16.7%), PDE7A (-1.6%), PDE7B (-2.1%), PDE8A (2.9%), PDE10A (1.6%), PDE11A (1.3%); In-vitro potency (Scintillation Proximity Assay): IC50(PDE1) = 0.753 nM, IC50(PDE2A) >10000 nM, IC50(PDE3B) >10000 nM, IC50(PDE4B) = 3960 nM, IC50(PDE5A) = 2980 nM, IC50(PDE6) = 1560 nM, IC50(PDE7B) >10000 nM, IC50(PDE8A) = 1490 nM, IC50(PDE10A) >10000 nM, IC50(PDE11A) = 6600 nM
Selectivity Source Knowledge
Compound image 
KB-130015
NR
THRB
IC50 = 2000
NR
3 µM
Compound EUbOPEN ID
EUB0002355a
SMILES
CC1=C(C2=CC=CC=C2O1)CC3=CC(=C(C(=C3)I)OCC(=O)O)I
InChIKey
OLIKCJUMYWSDIV-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
THRB1, THRB2, NR1A2, THR1, ERBA-BETA, GRTH
Mode of action
Antagonist
Affinity on-target cellular assay type
cell-based
Affinity on-target cellular source knowledge
Selectivity platform
Reportergenassay
Selectivity platform number of targets
26
Selectivity remarks
inactive at 3 µM for inactive at 1 µM for UL48, RXRA, HNF4A, NR2C1, NR2E1, NR4A1, NR5A1
Selectivity Source Knowledge
Compound image 
Oxatomide
NR
NR1I2
EC50 -- 6000
NR
10 µM
Compound EUbOPEN ID
EUB0002358a
SMILES
O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
InChIKey
BAINIUMDFURPJM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
ONR1, PXR, BXR, SXR, PAR2
Mode of action
Agonist
Affinity on-target cellular assay type
cell-based
Affinity on-target cellular source knowledge
Selectivity platform
Reportergenassay
Selectivity platform number of targets
26
Selectivity remarks
inactive at 10 µM for VDR, NR1I3, UL48, RXRA, HNF4A, NR2C1, NR2E1, NR4A1, NR5A1
Selectivity Source Knowledge
Compound image 
Famprofazone
NR
NR1I2
EC50 -- 130
NR
1 µM
Compound EUbOPEN ID
EUB0002359a
SMILES
CC(C)C1=C(N(N(C1=O)C2=CC=CC=C2)C)CN(C)C(C)CC3=CC=CC=C3
InChIKey
GNUXVOXXWGNPIV-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
ONR1, PXR, BXR, SXR, PAR2
Mode of action
Agonist
Affinity on-target cellular assay type
cell-based
Affinity on-target cellular source knowledge
Selectivity platform
Reportergenassay
Selectivity platform number of targets
26
Selectivity remarks
inactive at 1 µM for VDR, NR1I3, UL48, RXRA, HNF4A, NR2C1, NR2E1, NR4A1, NR5A1
Selectivity Source Knowledge
Compound image 
TR03307825
Protein Kinase
EGFR
IC50 = 6
IC50 = 120
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002414a
SMILES
Clc1cc(ccc1)Nc2ncnc3c2cc(c(c3)OC)OC
InChIKey
GFNNBHLJANVSQV-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
ERBB1
Mode of action
Inhibitor
Affinity biochemical assay type
Radiometric assay (conc. ATP = 0.4 µM)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
ELISA (inhibition of EGF-dependent tyrosine phosphorylation, using A431 cells)
Selectivity platform
Kinase panel (Millipore)
Selectivity platform number of targets
222
Selectivity remarks
Screened at 1 µM, closest targets as % of residual activity: EGFR (-5%), LYN(10%), BRSK1 (14%), full screening data are available at Chembl and in paper, also screened at 10 µM, https://pubmed.ncbi.nlm.nih.gov/23398362/;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(ABL1) = 125 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(SRC) >10000 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(PRKCA) >10000 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (ADP Hunter assay, conc. ATP = 100 µM): IC50(MNK1) = 530 nM, https://pubs.acs.org/doi/10.1021/jm1005513#_i23;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(ABL1) = 125 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(SRC) >10000 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (radiometric assay, conc. ATP = 0.4 µM): IC50(PRKCA) >10000 nM, https://pubmed.ncbi.nlm.nih.gov/10090785/;
In-vitro potency (ADP Hunter assay, conc. ATP = 100 µM): IC50(MNK1) = 530 nM, https://pubs.acs.org/doi/10.1021/jm1005513#_i23;
Selectivity Source Knowledge
Compound image 
Ceralasertib
Protein Kinase
ATR
IC50 = 1
IC50 = 74
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002888b
SMILES
O=[S@@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N
InChIKey
OHUHVTCQTUDPIJ-JYCIKRDWSA-N
NCBI gene ID
UniProt ID
Synonyms
FRP1, SCKL, SCKL1, MEC1
Mode of action
Inhibitor
Affinity biochemical assay type
Kinase-Glo assay (Promega)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
ELISA (ATR kinase-dependent CHK1 phosphorylation in HT29 cells)
Affinity on-target cellular source knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
442
Selectivity remarks
Screened at 1 µM, closest targets as % of inhibition: PI3KC2G (61%), CLK4 (57%), PIK3CD (47%), full screening data are available as supporting informationpubmed.ncbi.nlm.nih.gov/30346772/
In-cellular potency (cellular kinase assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(DNAPK) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(MTOR) >23 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(PIK3CA) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(ATR) = 0.134 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(ATM) > 10 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(DNAPK) = 7.4 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(MTOR) = 3.8 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(PIK3CA) >10 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-cellular potency (cellular kinase assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(DNAPK) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(MTOR) >23 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-cellular potency (cellular kinase assay): IC50(PIK3CA) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26517239/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(ATR) = 0.134 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(ATM) > 10 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(DNAPK) = 7.4 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(MTOR) = 3.8 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
In-vitro potency (enzymatic assay, Kinase Profiler Eurofins): IC50(PIK3CA) >10 µM, https://pubmed.ncbi.nlm.nih.gov/34911817/;
Selectivity Source Knowledge
Compound image 
AMG PERK 44
Protein Kinase
EIF2AK3
IC50 = 6
IC50 = 84
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002895aCl
SMILES
O=C1N(C2=CC=CC=C2)N(C)C(C3=CC=CC=C3)=C1C(C4=CC=C(C)C(C5=CC=C6N=C(C)C=CC6=C5)=C4N)=O.[H]Cl
InChIKey
YPPSMYLMSKHYAY-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
PEK, PERK
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay (Cisbio Inc., using 1 µM ATP (=Km) )
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
ELISA (phosphorylation of PERK (T980) using HT1080–T-REx–PERK–FLAG cells)
Affinity on-target cellular source knowledge
Selectivity platform
KINOMEscan (DiscoveRx)
Selectivity platform number of targets
387
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CSF1R (40%), NEK11 (41%), full screening data available as supporting information, https://pubmed.ncbi.nlm.nih.gov/25587754/;
Selectivity Source Knowledge
Compound image 
AR-A014418
Protein Kinase
GSK3A
IC50 = 0.028
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002897a
SMILES
O=C(NCC1=CC=C(OC)C=C1)NC2=NC=C([N+]([O-])=O)S2
InChIKey
YAEMHJKFIIIULI-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity biochemical assay type
Mobility shift microfluidic assay (Caliper, MA)
Affinity Biochemical Source Knowledge
Selectivity platform
KINOMEscan (DiscoveRx)
Selectivity platform number of targets
402
Selectivity remarks
Screened at 10 µM, closest targets as % of control: MST2 (3.4%), KIT(V5559D, 3.6%), PCTK1 (15%), RIOK2 (23%), STK16 (28%), YSK4 (49%), HIPK4 (49%), GSK3A (0.1%), GSK3B (11%), PRKX (42%), full screening data available as supporting information;
Selectivity Source Knowledge
Compound image 
AR-A014418
Protein Kinase
GSK3B
IC50 = 0.116
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002897a
SMILES
O=C(NCC1=CC=C(OC)C=C1)NC2=NC=C([N+]([O-])=O)S2
InChIKey
YAEMHJKFIIIULI-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity biochemical assay type
Mobility shift microfluidic assay (Caliper, MA)
Affinity Biochemical Source Knowledge
Selectivity platform
KINOMEscan (DiscoveRx)
Selectivity platform number of targets
402
Selectivity remarks
Screened at 10 µM, closest targets as % of control: MST2 (3.4%), KIT(V5559D, 3.6%), PCTK1 (15%), RIOK2 (23%), STK16 (28%), YSK4 (49%), HIPK4 (49%), GSK3A (0.1%), GSK3B (11%), PRKX (42%), full screening data available as supporting information;
Selectivity Source Knowledge
Compound image 
AZD0156
Protein Kinase
ATM
IC50 = 0.04
IC50 = 0.57
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002900a
SMILES
O=C(N(C1=C2C3=CC(C4=CC=C(N=C4)OCCCN(C)C)=CC=C3N=C1)C)N2C5CCOCC5
InChIKey
AOTRIQLYUAFVSC-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
TEL1, TELO1
Mode of action
Inhibitor
Affinity biochemical assay type
HTRF assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Immunoblot assay (phosphorylation of ATM at Ser1981, using HT-29 cells)
Affinity on-target cellular source knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
397
Selectivity remarks
Screened at 1 µM, closest targets as % of control: GSG2 (33%), PIK3CA (36%), PIK4CB (30%), LRRK2 (13%), MTOR (7.4%), full screening data are available as supporting information, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (Immunoblot assay, ATR dependent phosphorylation of CHEK1 at Ser345, using HT-29 cells): IC50(ATR) = 6.2 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (ELISA, PIK3CA dependent phosphorylation of AKT1 at Thr308 using BT474 cells): IC50(PIK3CA) = 1.4 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (Immunoblot assay, MTOR dependent phosphorylation of AKT1 at Ser473 using MDA-MB-468 cells): IC50(MTOR) = 0.61 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 0.14 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(MTOR) = 0.20 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CA) = 0.32 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 1.8 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CG) = 1.1 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CD) = 0.27 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (Immunoblot assay, ATR dependent phosphorylation of CHEK1 at Ser345, using HT-29 cells): IC50(ATR) = 6.2 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (ELISA, PIK3CA dependent phosphorylation of AKT1 at Thr308 using BT474 cells): IC50(PIK3CA) = 1.4 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-cellular potency (Immunoblot assay, MTOR dependent phosphorylation of AKT1 at Ser473 using MDA-MB-468 cells): IC50(MTOR) = 0.61 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 0.14 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(MTOR) = 0.20 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CA) = 0.32 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 1.8 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CG) = 1.1 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
In-vitro potency (enzymatic assay): IC50(PIK3CD) = 0.27 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01896;
Selectivity Source Knowledge
Compound image 
AZD1390
Protein Kinase
ATM
IC50 = 0.09
IC50 = 0.78
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002901a
SMILES
O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
InChIKey
VQSZIPCGAGVRRP-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
TEL1, TELO1
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Western Blot assay (using NCI-H2228 cells and anti-ATM pS1981 (ab81292) antibody)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (Thermo Fisher Scientific)
Selectivity platform number of targets
121
Selectivity remarks
Screened at 1 µM, closest targets with >50% of activity in the screen: CSF1R, NUAK1, SGK, screening data are not available in paper, https://pubmed.ncbi.nlm.nih.gov/29938225/;
Screened at 1 µM, against 125 kinases, Eurofins Panlabs screen, closest target with >50% of activity in the screen: FMS, screening data are not available in paper, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(PIK3CA) >12 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(MTOR) >16.1 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(DNAPK) >29.9 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(HERG) = 6.55 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
Screened at 1 µM, against 125 kinases, Eurofins Panlabs screen, closest target with >50% of activity in the screen: FMS, screening data are not available in paper, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(PIK3CA) >12 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(MTOR) >16.1 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(DNAPK) >29.9 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
In-vitro potency (enzymatic assay): IC50(HERG) = 6.55 µM, https://pubmed.ncbi.nlm.nih.gov/29938225/;
Selectivity Source Knowledge
Compound image 
BMS-986176
Protein Kinase
AAK1
IC50 = 2
IC50 = 2
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002902a
SMILES
CC(C)C[C@@](N)(C)COC1=C(C(F)F)N=C(C2=CC(C(F)F)=NC=C2)C=C1
InChIKey
RKAHOQATMSONTM-IBGZPJMESA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA1048, DKFZp686K16132
Mode of action
Inhibitor
Affinity biochemical assay type
Caliper assay (using 22 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Western Blot assay (inhibition of AAK1 phosphorylation using HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (literature)
Selectivity platform number of targets
396
Selectivity remarks
Screened at 1 µM, closest targets in the screen: BIKE, CRIK, MNK1, MNK2, % of inhibition not given in paper, https://pubmed.ncbi.nlm.nih.gov/35257579/;
Screened against panel of 249 kinases (literature), in-vitro potency of closest targets:
In-vitro potency (enzymatic assay): IC50(BIKE) = 1900 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(GAK) = 800 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(CRIK) = 410 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(LATS2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(MKN1) = 160 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
Screened at CEREB-like safety panel (literature) against 41 targets, in-vitro potency of closest target: IC50(NET) = 390 nM, all other targets >6 µM https://pubmed.ncbi.nlm.nih.gov/35257579/;
Screened against panel of 249 kinases (literature), in-vitro potency of closest targets:
In-vitro potency (enzymatic assay): IC50(BIKE) = 1900 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(GAK) = 800 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(CRIK) = 410 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(LATS2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
In-vitro potency (enzymatic assay): IC50(MKN1) = 160 nM, https://pubmed.ncbi.nlm.nih.gov/35257579/;
Screened at CEREB-like safety panel (literature) against 41 targets, in-vitro potency of closest target: IC50(NET) = 390 nM, all other targets >6 µM https://pubmed.ncbi.nlm.nih.gov/35257579/;
Selectivity Source Knowledge
Compound image 
CC-115
Protein Kinase
PRKDC
IC50 = 13
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002910aCl
SMILES
[H]Cl.O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
InChIKey
GMYLVKUGJMYTFB-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
DNPK1, p350, DNAPK, XRCC7, DNA-PKcs, DNAPKc, DNA-PKC, p460
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (Invitrogen’s SelectScreen™ profiling)
Selectivity platform number of targets
250
Selectivity remarks
Screened at 3 µM, closest targets as % of activity remaining: MTOR (0%), FMS (43%), full screening data are available as supplemental information, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (HTR-FRET assay): IC50(PIK3CA) = 0.852 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (HTR-FRET assay): IC50(PIK3CA) = 0.852 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
Selectivity Source Knowledge
Compound image 
CC-115
Protein Kinase
MTOR
IC50 = 21
IC50 = 23
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002910aCl
SMILES
[H]Cl.O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
InChIKey
GMYLVKUGJMYTFB-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
RAFT1, RAPT1, FLJ44809
Mode of action
Inhibitor
Affinity biochemical assay type
HTR-FRET assay (using 15 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
MesoScale assay (phosphorylation of 70S6K using PC3 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (Invitrogen’s SelectScreen™ profiling)
Selectivity platform number of targets
250
Selectivity remarks
Screened at 3 µM, closest targets as % of activity remaining: MTOR (0%), FMS (43%), full screening data are available as supplemental information, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (HTR-FRET assay): IC50(PIK3CA) = 0.852 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (HTR-FRET assay): IC50(PIK3CA) = 0.852 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATM) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
In-vitro potency (enzymatic assay): IC50(ATR) >30 µM, https://pubmed.ncbi.nlm.nih.gov/26102506/;
Selectivity Source Knowledge
Compound image 
CQ211
Protein Kinase
RIOK2
Kd = 6.1
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002914a
SMILES
O=C1C2=C(C3=CC(C4=CC=C(N=C4)OC)=CC=C3N1)N(N=N2)C5=CC=C(C(C(F)(F)F)=C5)N6CCNCC6
InChIKey
RGHLRMNPUGUZEY-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
FLJ11159
Mode of action
Inhibitor
Affinity biochemical assay type
Competition binding assay (DiscoverX)
Affinity Biochemical Source Knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
468
Selectivity remarks
Screened at 1 µM, closest targets as % of control: FLT3 (ITD, D835V, 4%), FLT3 (ITD, F691L, 3.6%), RIOK1 (100%), RIOK2 (0%), RIOK3 (87%), full screening data are available as supporting information;
Selectivity Source Knowledge
Compound image 
Elimusertib
Protein Kinase
ATR
IC50 = 7
IC50 = 36
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002916a
SMILES
CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2
InChIKey
YBXRSCXGRPSTMW-CYBMUJFWSA-N
NCBI gene ID
UniProt ID
Synonyms
FRP1, SCKL, SCKL1, MEC1
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
ATR cellular mechanistic assay in HT-29 cells
Affinity on-target cellular source knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
468
Selectivity remarks
Screened at 1 µM, closest targets as % of control: MTOR (2.2%), DYRK1B (11%), VSP34 (17%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(DYRK1B) = 25000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GAK) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GSK3B) >30000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(RIOK2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(VSP34) = 3200 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 332 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (TR-FRET assay): IC50(ATM) = 1420 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 3270 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(DYRK1B) = 25000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GAK) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GSK3B) >30000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(RIOK2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(VSP34) = 3200 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 332 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (TR-FRET assay): IC50(ATM) = 1420 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 3270 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
Selectivity Source Knowledge
Compound image 
Elimusertib
Protein Kinase
MTOR
Kd = 24
IC50 = 135
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002916a
SMILES
CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2
InChIKey
YBXRSCXGRPSTMW-CYBMUJFWSA-N
NCBI gene ID
UniProt ID
Synonyms
RAFT1, RAPT1, FLJ44809
Mode of action
Inhibitor
Affinity biochemical assay type
Competition binding assay (DiscoverX)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
AlphaScreen assay (mTOR endogenous kinase activity in unstimulated HeLa S3 cells using pP70S6K(Thr389) as substrate)
Affinity on-target cellular source knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
468
Selectivity remarks
Screened at 1 µM, closest targets as % of control: MTOR (2.2%), DYRK1B (11%), VSP34 (17%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(DYRK1B) = 25000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GAK) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GSK3B) >30000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(RIOK2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(VSP34) = 3200 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 332 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (TR-FRET assay): IC50(ATM) = 1420 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 3270 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(DYRK1B) = 25000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GAK) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(GSK3B) >30000 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(RIOK2) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (Competition binding assay, DiscoverX): Kd(VSP34) = 3200 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 332 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (TR-FRET assay): IC50(ATM) = 1420 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
In-vitro potency (enzymatic assay): IC50(PIK3CB) = 3270 nM, https://pubmed.ncbi.nlm.nih.gov/32502336/;
Selectivity Source Knowledge
Compound image 
GCN2iB
Protein Kinase
EIF2AK4
IC50 = 2.4
EC50 > 80
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002919a
SMILES
O=S(C1=CC(Cl)=CN=C1OC)(NC2=CC=C(F)C(C#CC3=CN=C(N)N=C3)=C2F)=O
InChIKey
JGHVXJKGYJYWOP-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity biochemical assay type
Lantha Screen assay (LanthaScreen Tb-anti-p-eIF2α (pSer52) antibody kit (Thermo Fisher Scientific) using ATP = Km)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Western Blot assay (phosphorylation of GCN2 using CCRF-CEM cells)
Affinity on-target cellular source knowledge
Selectivity platform
KINOMEscan (DiscoveRx)
Selectivity platform number of targets
468
Selectivity remarks
Screened at 1 µM, closest targets >95 % of control: MAP2K5, STK10, ZAK, GSK3B (100%) further targets not named;
Selectivity Source Knowledge
Compound image 
GNE-8505
Protein Kinase
MAP3K12
IC50 = 10
IC50 = 77.6
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002923a
SMILES
FC(F)(F)C1=CC(C2=NN(C([C@@H]3[C@]4([H])[C@@]3([H])CN(C5COC5)C4)=C2)CC6CC6)=CN=C1N
InChIKey
IRPVABHDSJVBNZ-QWHZDKJVSA-N
NCBI gene ID
UniProt ID
Synonyms
MUK, DLK, ZPKP1, MEKK12
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Immunoblot assay (JNK phosphorylation in HEK293 cells overexpressing DLK, calculated serum-free assay)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (invitrogen)
Selectivity platform number of targets
220
Selectivity remarks
Screened at 1 µM, closest targets as % of control: FLT3 (67%), DMPK (58%), AXL (57%), NTRK1 (56%), CSF1R (54%), EPHA7 (51%), further screening data not shown in paper, https://pubmed.ncbi.nlm.nih.gov/28814543/;
Selectivity Source Knowledge
Compound image 
GNE-8505
Protein Kinase
MAP3K13
IC50 = 62
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002923a
SMILES
FC(F)(F)C1=CC(C2=NN(C([C@@H]3[C@]4([H])[C@@]3([H])CN(C5COC5)C4)=C2)CC6CC6)=CN=C1N
InChIKey
IRPVABHDSJVBNZ-QWHZDKJVSA-N
NCBI gene ID
UniProt ID
Synonyms
LZK, MEKK13
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (invitrogen)
Selectivity platform number of targets
220
Selectivity remarks
Screened at 1 µM, closest targets as % of control: FLT3 (67%), DMPK (58%), AXL (57%), NTRK1 (56%), CSF1R (54%), EPHA7 (51%), further screening data not shown in paper, https://pubmed.ncbi.nlm.nih.gov/28814543/;
Selectivity Source Knowledge
Compound image 
GS-444217
Protein Kinase
MAP3K5
IC50 = 2.87
EC50 < 1000
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002924a
SMILES
O=C(C1=NC=CC(N2C=C(C3CC3)N=C2)=C1)NC4=CC=CC(C5=NN=CN5C6CC6)=C4
InChIKey
ZGCMQKWOUIMBEP-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
MAPKKK5, ASK1
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay (using 100 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Western Blot assay (inhibition of MAP3K5 phosphorylation in HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
442
Selectivity remarks
Screened at 1 µM, S-Score(35) = 0.01, closest targets with >35% of inhibition: RPS6KA6, DYRK1A, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(RPS6KA6) = 430 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(DYRK1A) = 220 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(MAP3K5) = 4.1 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(RPS6KA6) = 430 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(DYRK1A) = 220 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
In-vitro potency (competition-binding assay, DiscoverX): Kd(MAP3K5) = 4.1 nM, https://pubmed.ncbi.nlm.nih.gov/30024858/;
Selectivity Source Knowledge
Compound image 
IRE1α kinase-IN-1
Protein Kinase
ERN1
IC50 = 77
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002930a
SMILES
CN1CCC(CNC2=CC(Cl)=NN3C2=NC=C3C4=C(F)C=C5C(N=C(NC6=CC=CC=C6)N5)=C4)CC1
InChIKey
BPRAHARGXSNSSO-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
IRE1, IRE1P
Mode of action
Inhibitor
Affinity biochemical assay type
LanthaScreen Eu Kinase binding FRET assay
Affinity Biochemical Source Knowledge
Selectivity platform
KINOMEscan (Eurofins)
Selectivity platform number of targets
455
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CLK4 (20%), ERN1 (33%), GAK (33%), KIT(V559D/V654A, 27%), CDK17 (2.7%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/30779566/;
In-vitro potency (LanthaScreen Eu Kinase binding FRET assay): IC50(ERN2) = 7682 nM, https://pubmed.ncbi.nlm.nih.gov/30779566/;
In-vitro potency (LanthaScreen Eu Kinase binding FRET assay): IC50(ERN2) = 7682 nM, https://pubmed.ncbi.nlm.nih.gov/30779566/;
Selectivity Source Knowledge
Compound image 
KU-60019
Protein Kinase
ATM
IC50 = 6.3
IC50 = 150
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002933a
SMILES
C[C@@H]1O[C@@H](CN(CC(NC2=CC3=C(C=C2)SC4=C(C3)C=CC=C4C5=CC(C=C(O5)N6CCOCC6)=O)=O)C1)C
InChIKey
SCELLOWTHJGVIC-BGYRXZFFSA-N
NCBI gene ID
UniProt ID
Synonyms
TEL1, TELO1
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Immunoblot assay (phosphorylation of ATM at Ser1981, using HT-29 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Millipore KinaseProfiler
Selectivity platform number of targets
229
Selectivity remarks
Screened at 1 µM, closest targets as % of activity: FMS (46%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/19808981/;
Screened at 1 µM, PI3-Kinase HTRF assay, closest targets: PIK3CB (9%), PIK3CG (3%), screening data are not available in paper, https://pubmed.ncbi.nlm.nih.gov/19808981/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 17 µM, https://pubmed.ncbi.nlm.nih.gov/19808981/;
In-vitro potency (enzymatic assay): IC50(ATR) >10 µM, https://pubmed.ncbi.nlm.nih.gov/19808981/;
Screened at 1 µM, PI3-Kinase HTRF assay, closest targets: PIK3CB (9%), PIK3CG (3%), screening data are not available in paper, https://pubmed.ncbi.nlm.nih.gov/19808981/;
In-vitro potency (enzymatic assay): IC50(DNAPK) = 17 µM, https://pubmed.ncbi.nlm.nih.gov/19808981/;
In-vitro potency (enzymatic assay): IC50(ATR) >10 µM, https://pubmed.ncbi.nlm.nih.gov/19808981/;
Selectivity Source Knowledge
Compound image 
LP-935509
Protein Kinase
AAK1
IC50 = 3.3
IC50 = 2.8
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002937a
SMILES
O=C(N1CCN(C2=NC3=C(C4=CC=CN=C4OC)C=NN3C=C2)CC1)OC(C)C
InChIKey
GOOYSJIWTIHOGW-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA1048, DKFZp686K16132
Mode of action
Inhibitor
Affinity biochemical assay type
Caliper enzyme assay (phosphorylation of peptide substrate, using 22 µM ATP = Km)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Western Blot assay (inhibition of MU-2 phosphorylation using HEK293 cells with adaptor protein 2 (AP-2))
Affinity on-target cellular source knowledge
Selectivity platform
KINOMEscan (AMBIT/DiscoveRx)
Selectivity platform number of targets
389
Selectivity remarks
Screened at 1 µM, closest targets as % of control: AAK1 (2.1%), PRP4 (28%). RIOK1 (3.9%), RIOK3 (6.6%), BIKE (3.5%), SGK085 (7.6%), SGK288 (13%), SRPK1 (19%), SRPK2 (28%), LBK1 (9.7%), DRAK1 (6.4%), DRAK2 (30%), PIP5K2C (9.5%), full screening data arae available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 43 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(PDE4) = 8.3 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 8 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(α2A ) >1 µM, IC50(α2C) >1 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 43 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(PDE4) = 8.3 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 8 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(α2A ) >1 µM, IC50(α2C) >1 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Selectivity Source Knowledge
Compound image 
LP-935509
Protein Kinase
BIKE
IC50 = 14
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002937a
SMILES
O=C(N1CCN(C2=NC3=C(C4=CC=CN=C4OC)C=NN3C=C2)CC1)OC(C)C
InChIKey
GOOYSJIWTIHOGW-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity biochemical assay type
Caliper enzyme assay (phosphorylation of peptide substrate, using 3.3 µM ATP = Km)
Affinity Biochemical Source Knowledge
Selectivity platform
KINOMEscan (AMBIT/DiscoveRx)
Selectivity platform number of targets
389
Selectivity remarks
Screened at 1 µM, closest targets as % of control: AAK1 (2.1%), PRP4 (28%). RIOK1 (3.9%), RIOK3 (6.6%), BIKE (3.5%), SGK085 (7.6%), SGK288 (13%), SRPK1 (19%), SRPK2 (28%), LBK1 (9.7%), DRAK1 (6.4%), DRAK2 (30%), PIP5K2C (9.5%), full screening data arae available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 43 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(PDE4) = 8.3 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 8 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(α2A ) >1 µM, IC50(α2C) >1 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 43 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(PDE4) = 8.3 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Screened against 8 receptors, transporters, and enzymes (enzymatic assays), closest target: IC50(α2A ) >1 µM, IC50(α2C) >1 µM, full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27411717/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
PKMYT1
IC50 = 3.1
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
MYT1, PPP1R126
Mode of action
Inhibitor
Affinity biochemical assay type
ADP-Glo assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
AlphaLISA (PKMYT1 dependent phoshorylation of CDK1 at Thr14 using FUOV1 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
EPHA1
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
EPH
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
EPHA2
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
EPHB2
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
Hek5, Tyro5
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
EPHB3
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
Hek2, Tyro6
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
EPHB4
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
Tyro11
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
RP-6306
Protein Kinase
WEE1
IC50 = 14, 58, 138, 378, 262, 276, 4.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002949a
SMILES
O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N
InChIKey
ARBRHWRTXPWZGN-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
WEE1A
Mode of action
Inhibitor
Affinity on-target cellular assay type
NanoBRET assay (HEK293 cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinativ Colo-205 cell lysate kinase binding assay
Selectivity platform number of targets
274
Selectivity remarks
Screened at 1.2 µM (85-fold ist cellular IC50), closest targets in the screen: EPHA1, EPHA2, EPHB2, EPHB3, EPHB4, FRK, SRC, WEE1;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(FRK) = 1.14 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(SRC) >8.3 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
In-cellular potency (NanoBRET assay, HEK293 cells): IC50(WEE1) = 4.1 µM, https://pubmed.ncbi.nlm.nih.gov/35880755/;
Selectivity Source Knowledge
Compound image 
Simurosertib
Protein Kinase
CDC7
IC50 < 0.3
Kinase set
100 nM
Compound EUbOPEN ID
EUB0002995a
SMILES
O=C1C2=C(C=C(C3=CNN=C3C)S2)NC([C@H]4N(CC5)CCC5C4)=N1
InChIKey
XGVXKJKTISMIOW-ZDUSSCGKSA-N
NCBI gene ID
UniProt ID
Synonyms
Hsk1, huCdc7, HsCdc7
Mode of action
Inhibitor
Affinity biochemical assay type
TR-FRET assay (using CDC7/DBF4 protein, using 50 µM ATP)
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (SelectScreen Kinase Profiling, Invitrogen)
Selectivity platform number of targets
318
Selectivity remarks
Screened at 1 µM, the closest targets as % of inhibition: DAPK3 (98.8%), DAKP1 (96.1%), CDK9/cyclin T1 (94.7%), DMPK (94.1%), CDK8/cyclin C (91.0%), MAPK12 (85.1%), STK17A (84.4%), CLK4 (84.1%), DYRK1A (82.0%), GSK3B (80.5%), other kinases <80%, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency of closest targets:
In-vitro potency (Adapta assay): IC50(DAPK3) = 160 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Adapta assay): IC50(DAPK1) = 49.8 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CDK9/cyclin T1) = 36.9 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(DMPK) = 44.2 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CDK8/cyclin C) = 101 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(MAPK12) = 155 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(STK17A) = 115 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CLK4) = 99 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(DYRK1A) = 148 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(GSK3B) = 338 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay): IC50(CDK2) = 6300 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (biochemical assay): Kd(CDC7) = 0.424 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency of closest targets:
In-vitro potency (Adapta assay): IC50(DAPK3) = 160 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Adapta assay): IC50(DAPK1) = 49.8 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CDK9/cyclin T1) = 36.9 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(DMPK) = 44.2 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CDK8/cyclin C) = 101 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(MAPK12) = 155 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(STK17A) = 115 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (LanthaScreen Eu kinase binding assay): IC50(CLK4) = 99 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(DYRK1A) = 148 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay, using 100 µM ATP): IC50(GSK3B) = 338 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (Z′-LYTE biochemical assay): IC50(CDK2) = 6300 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
In-vitro potency (biochemical assay): Kd(CDC7) = 0.424 nM, https://pubmed.ncbi.nlm.nih.gov/31131319/;
Compound image 
TAK1/MAP4K2 inhibitor 1
Protein Kinase
MAP3K7
IC50 = 41.1
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002999a
SMILES
CC(N1)=CC2=C1N=CN=C2OC3=C(C)C=CC(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)=C3
InChIKey
RWNAOXLCVXJMGM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
MEKK7
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
KiNative profiling (Proteomics)
Selectivity platform number of targets
>200
Selectivity remarks
Screened at 1 µM, using HUH7 cell lysate, closest target as % of inhibition: FER (82.7%), https://pubmed.ncbi.nlm.nih.gov/25075558/;
Selectivity Source Knowledge
Compound image 
TAK1/MAP4K2 inhibitor 1
Protein Kinase
MAP4K2
IC50 = 18.2
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002999a
SMILES
CC(N1)=CC2=C1N=CN=C2OC3=C(C)C=CC(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)=C3
InChIKey
RWNAOXLCVXJMGM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
GCK, BL44
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
KiNative profiling (Proteomics)
Selectivity platform number of targets
>200
Selectivity remarks
Screened at 1 µM, using HUH7 cell lysate, closest target as % of inhibition: FER (82.7%), https://pubmed.ncbi.nlm.nih.gov/25075558/;
Selectivity Source Knowledge
Compound image 
TAK1/MAP4K2 inhibitor 1
Protein Kinase
FES
IC50 = 69.7
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002999a
SMILES
CC(N1)=CC2=C1N=CN=C2OC3=C(C)C=CC(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)=C3
InChIKey
RWNAOXLCVXJMGM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
FPS
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
KiNative profiling (Proteomics)
Selectivity platform number of targets
>200
Selectivity remarks
Screened at 1 µM, using HUH7 cell lysate, closest target as % of inhibition: FER (82.7%), https://pubmed.ncbi.nlm.nih.gov/25075558/;
Selectivity Source Knowledge
Compound image 
TAK1/MAP4K2 inhibitor 1
Protein Kinase
FER
IC50 = 74.8
Kinase set
1 µM
Compound EUbOPEN ID
EUB0002999a
SMILES
CC(N1)=CC2=C1N=CN=C2OC3=C(C)C=CC(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)=C3
InChIKey
RWNAOXLCVXJMGM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
TYK3, PPP1R74
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
KiNative profiling (Proteomics)
Selectivity platform number of targets
>200
Selectivity remarks
Screened at 1 µM, using HUH7 cell lysate, closest target as % of inhibition: FER (82.7%), https://pubmed.ncbi.nlm.nih.gov/25075558/;
Selectivity Source Knowledge
Compound image 
TAK1-IN-2
Protein Kinase
MAP3K7
IC50 = 2
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003000a
SMILES
O=C(C1=CC2=C(CN(C(C3=NC(C(N(CC4=CC=CC=C4OC(F)F)[C@H](C)C(NC)=O)=O)=CN3)=O)C2)C=C1)N
InChIKey
QEAYKBGEHPZBIL-CQSZACIVSA-N
NCBI gene ID
UniProt ID
Synonyms
MEKK7
Mode of action
Inhibitor
Affinity biochemical assay type
LanthaScreen assay (10 µM ATP)
Affinity Biochemical Source Knowledge
Selectivity platform
KinomeScan (DiscoverX)
Selectivity platform number of targets
468
Selectivity remarks
Screened at 1 µM, closest targets as % of control: CSNK2A1 (25%), CSNK2A2 (7.3%), LRRK2 (45%), PIK3CD (32%), PIK3CG(37%), PIP5K1C (7.3%), MAP3K7 (0.85%), full screening data available as supporting information,https://pubmed.ncbi.nlm.nih.gov/33859795/;
Selectivity Source Knowledge
Compound image 
Vatalanib
Protein Kinase
KDR
IC50 = 37
IC50 = 17
Kinase set
100 nM
Compound EUbOPEN ID
EUB0003003aCl
SMILES
ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1.[H]Cl.[H]Cl
InChIKey
YCOYDOIWSSHVCK-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
FLK1, VEGFR, VEGFR2, CD309
Mode of action
Inhibitor
Affinity biochemical assay type
Radiometric filter binding assay (using 8 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Immunoblot assay (cell-based receptor autophosphorylation assays using HUVECs that naturally express KDR)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (Competition-binding assay)
Selectivity platform number of targets
317
Selectivity remarks
Screened in competition binding assays, in-vitro potency of closest targets: Kd(CSF1R) = 18 nM, Kd(DDR1) = 270 nM, Kd(FLT1) = 9.6 nM, Kd(FLT4) = 330 nM, Kd(KIT) = 5.1 nM, Kd(PDGFRA) = 96 nM, Kd(PDGFRB) = 25 nM, Kd(VEGFR2) = 62 nM, full screening data are available as supporting information, https://www.nature.com/articles/nbt1358;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLT1) = 77 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLK) = 270 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLT4) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(KIT) = 730 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FMS) = 1400 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(PDGFRB) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLT1) = 77 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLK) = 270 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FLT4) = 660 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(KIT) = 730 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(FMS) = 1400 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
In-vitro potency (Radiometric assay, using 8 µM ATP): IC50(PDGFRB) = 580 nM, https://pubmed.ncbi.nlm.nih.gov/10786682/;
Selectivity Source Knowledge
Compound image 
XL413
Protein Kinase
CDC7
IC50 = 3.4
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003007aCl
SMILES
O=C1C2=C(N=C(N1)[C@@H]3CCCN3)C4=CC(Cl)=CC=C4O2.[H]Cl
InChIKey
JJWLXRKVUJDJKG-VIFPVBQESA-N
NCBI gene ID
UniProt ID
Synonyms
Hsk1, huCdc7, HsCdc7
Mode of action
Inhibitor
Affinity biochemical assay type
Luciferase-luciferin-coupled chemiluminescence assay (using 1 µM ATP)
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (Proteomica, Kinobead assay)
Selectivity platform number of targets
263
Selectivity remarks
Screened in competition binding assays usisng K-562, COLO 205, SK-N-BE(2) and MV-4-11 cell lysates, in-vitro potency of closest targets: Kd(DYRK1A) = 40 nM, Kd(CSNK2A1) = 22 nM, Kd(PIM1) = 22 nM, Kd(TAO3) = 2292 nM, Kd(CIT) = 3659 nM, Kd(GSK3B) = 8793 nM, all other targets Kd >3000 nM, full screening data are available at Chembl;
Selectivity Source Knowledge
Compound image 
XL413
Protein Kinase
PIM1
IC50 = 42
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003007aCl
SMILES
O=C1C2=C(N=C(N1)[C@@H]3CCCN3)C4=CC(Cl)=CC=C4O2.[H]Cl
InChIKey
JJWLXRKVUJDJKG-VIFPVBQESA-N
NCBI gene ID
UniProt ID
Mode of action
Inhibitor
Affinity biochemical assay type
Luciferase-luciferin-coupled chemiluminescence assay (using 0.5 µM ATP)
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (Proteomica, Kinobead assay)
Selectivity platform number of targets
263
Selectivity remarks
Screened in competition binding assays usisng K-562, COLO 205, SK-N-BE(2) and MV-4-11 cell lysates, in-vitro potency of closest targets: Kd(DYRK1A) = 40 nM, Kd(CSNK2A1) = 22 nM, Kd(PIM1) = 22 nM, Kd(TAO3) = 2292 nM, Kd(CIT) = 3659 nM, Kd(GSK3B) = 8793 nM, all other targets Kd >3000 nM, full screening data are available at Chembl;
Selectivity Source Knowledge
Compound image 
XST-14
Protein Kinase
ULK1
IC50 = 26.6
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003008a
SMILES
O=C(OC)C1=CC2=C(OC(C)C)C=C(OC(C)C)C=C2N1
InChIKey
ZNFMBFABCSHXPM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
ATG1, ATG1A
Mode of action
Inhibitor
Affinity biochemical assay type
ADP-Glo assay
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (SelectScreen Kinase Profiling Services)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 5 µM, closest targets >75% inhibition: MAP2K1, MAPK14, TGFBR2, ACVR1, CAMK2A, details an targets are not listed in the paper;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
Selectivity Source Knowledge
Compound image 
XST-14
Protein Kinase
ULK2
IC50 = 70.9
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003008a
SMILES
O=C(OC)C1=CC2=C(OC(C)C)C=C(OC(C)C)C=C2N1
InChIKey
ZNFMBFABCSHXPM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA0623, Unc51.2, ATG1B
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (SelectScreen Kinase Profiling Services)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 5 µM, closest targets >75% inhibition: MAP2K1, MAPK14, TGFBR2, ACVR1, CAMK2A, details an targets are not listed in the paper;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
Selectivity Source Knowledge
Compound image 
XST-14
Protein Kinase
CAMK2A
IC50 = 66.3
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003008a
SMILES
O=C(OC)C1=CC2=C(OC(C)C)C=C(OC(C)C)C=C2N1
InChIKey
ZNFMBFABCSHXPM-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA0968, CaMKIINalpha, CaMKIIa
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Selectivity platform
Kinase panel (SelectScreen Kinase Profiling Services)
Selectivity platform number of targets
403
Selectivity remarks
Screened at 5 µM, closest targets >75% inhibition: MAP2K1, MAPK14, TGFBR2, ACVR1, CAMK2A, details an targets are not listed in the paper;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAP2K1) = 721.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(MAPK14) = 283.9 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(TGFBR2) = 809.3 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
In-vitro potency (enzymatic assay): IC50(ACVR1) = 183.8 nM, https://pubmed.ncbi.nlm.nih.gov/31986961/;
Selectivity Source Knowledge
Compound image 
AX-15836
Protein Kinase
MAPK7
IC50 = 8
IC50 = 9
Kinase set
1 µM
Compound EUbOPEN ID
EUB0003009a
SMILES
O=C1N(C)C2=CN=C(NC3=CC=C(C(N4CCC(N5CCN(C)CC5)CC4)=O)C=C3OCC)N=C2N(S(=O)(C)=O)C6=CC=CC=C16
InChIKey
HTFNVAVTYILUCF-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
BMK1, ERK5
Mode of action
Inhibitor
Affinity biochemical assay type
Enzymatic assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
Cellular assay (KiNative using HUVEC cells)
Affinity on-target cellular source knowledge
Selectivity platform
Kinase panel (KiNative chemoproteomics profiling, Jurkat cells)
Selectivity platform number of targets
>200
Selectivity remarks
Screened at 1 µM, closest targets as % of inhibition: MAPK7 (99.2%), SRPK1 (35%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27679845/;
Screened at 10 µM, Kinase panel (KiNative chemoproteomics profiling, Jurkat cells), >200 kinases, closest targets as % of inhibition: MAPK7 (96.1%), NLK1 (41.7%), CDK7 (40.1%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27679845/;
Screened at 10 µM, Kinase panel (KiNative chemoproteomics profiling, Jurkat cells), >200 kinases, closest targets as % of inhibition: MAPK7 (96.1%), NLK1 (41.7%), CDK7 (40.1%), full screening data are available as supporting information, https://pubmed.ncbi.nlm.nih.gov/27679845/;
Selectivity Source Knowledge
Compound image 
C3TD879
Protein Kinase
CIT
IC50 = 12
Kd = 0.3
Kinase set
2 µM
Compound EUbOPEN ID
EUB0003024a
SMILES
Cc1cc(ccc1c1ccnc2c1cc(C)[nH]2)NC([C@@H](CC(C)(C)C)N)=O
InChIKey
ODOJVROSIRINJT-LJQANCHMSA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA0949, STK21, CRIK, CITK
Mode of action
Inhibitor
Negative control
C3TD879
Affinity biochemical assay type
LANCE TR-FRET assay (using 10 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET Assay (NanoLuc, inhibition of kinase domain, using HEK293T cells)
Affinity on-target cellular source knowledge
Selectivity platform
Eurofins KinaseProfiler assay
Selectivity platform number of targets
373
Selectivity remarks
Screened at 1 µM, closest targets as % of control: AAK1 (13%), MNK2 (35%), ACK1 (39%), BIKE (50%), full screening data are available as supporting information;
In-vitro potency (enzymatic assay): IC50(AAK1) = 212 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(BIKE) = 902 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(MNK2) = 2180 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(HIPK4) = 2275 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(ACK1) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(DRAK2) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AAK1) = 6.2 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(BMP2K) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(MKNK2) = 5.5 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(HIPK4) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(STK17B) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKB) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(GAK) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(PRKACA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (enzymatic assay): IC50(AAK1) = 212 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(BIKE) = 902 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(MNK2) = 2180 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(HIPK4) = 2275 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(ACK1) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(DRAK2) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AAK1) = 6.2 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(BMP2K) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(MKNK2) = 5.5 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(HIPK4) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(STK17B) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKB) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(GAK) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(PRKACA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
Selectivity Source Knowledge
Compound image 
C3TD879 NC
Protein Kinase
CIT
IC50 > 30000
Kd > 10000
Kinase set
2 µM
Compound EUbOPEN ID
EUB0003025a
SMILES
Cc1cc(ccc1c1cncc2c1cc(C)[nH]2)NC([C@@H](CC(C)(C)C)N)=O
InChIKey
HHXRZSZBSWPCKL-LJQANCHMSA-N
NCBI gene ID
UniProt ID
Synonyms
KIAA0949, STK21, CRIK, CITK
Mode of action
Negative control for C3TD879
Affinity biochemical assay type
LANCE TR-FRET assay (using 10 µM ATP)
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
NanoBRET Assay (HEK293T cells)
Affinity on-target cellular source knowledge
Compound image 
JNJ-78732576
Apoptosis regulator
MCL1
Ki = 115
AC50 > 30000
Other targets set
10 µM
Compound EUbOPEN ID
EUB0003044a
SMILES
CC1=C(C(O)=O)N(CCCOC2=CC(CCC3=CC(CSCC4=C5C(C)=NN4CCOCCOC)=NN3C)=CC6=C2C=C(Cl)C(F)=C6)C7=C1C5=C(Cl)C=C7
InChIKey
NQKQXMWUXJEWJR-UHFFFAOYSA-N
NCBI gene ID
UniProt ID
Synonyms
BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1, TM, bcl2-L-3, mcl1/EAT
Mode of action
Negative control for JNJ-4355
Affinity biochemical assay type
HTRF assay
Affinity Biochemical Source Knowledge
Affinity on-target cellular assay type
MOLP-8 Caspase Glo assay (using human MOLP8 cells)
Affinity on-target cellular source knowledge
Compound image 
TP-030n
Protein Kinase
RIPK1
Ki = 6900
Kinase set
100 nM
Compound EUbOPEN ID
EUB0003063a
SMILES
CN1C([C@@H](N2CCC3=CN(N=C3C2=O)CC4CCS(CC4)(=O)=O)COC5=CC=CC=C15)=O
InChIKey
IVVSBEQDCAZLFY-SFHVURJKSA-N
NCBI gene ID
UniProt ID
Synonyms
RIP
Mode of action
Negative control for TP_030_1 and TP_030_2
Affinity biochemical assay type
TR-FRET binding assay (Invitrogen)
Affinity Biochemical Source Knowledge
Compound image 